

ASX Announcement

Medibio Limited – 11 January 2021



Medibio's Patent-Protected Consumer Mental Health App, Commences Initial Testing Phase

Melbourne, Australia and Minneapolis, MN – 11 January 2021: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF) today announces it has commenced the initial phase of testing of its consumer mental health app (Consumer App).

The Company's pioneering work in the use of biometric data to aid in the early detection and screening of mental health conditions, together with **its patented method of assessing stress by monitoring overnight heart rate¹**, underpins the functionality of the Consumer App, which includes both biometric and psychometric assessments.

The Consumer App's unique biometric functionality matches day and night heart rate activity and its variability throughout the night (drawn from wearable devices such as Garmin or the Apple Watch) against sleep architecture parameters and physical activity levels, producing an overall daily score to help users objectively measure, monitor, and manage stress levels and improve them over time. This unique feature will set it apart from competitors in the marketplace. Our market research indicates no other viable in-store mental health app has patent protected biometric functionality.

The Consumer App will also support users whom do not have a wearable device, through its interactive psychometric assessment feature, which utilizes a clinically validated questionnaire to indicate stress levels.

In 2018 (pre-COVID) the estimated market size of global mHealth apps (using smartphones to keep track of well-being) was US\$12.4 billion and projected to expand at a compound annual growth rate of 44.7% through 2026². The COVID-19 pandemic and its many social and economic consequences has exacerbated mental health conditions among the global population. In the United States, the increased stress and worry has adversely impacted the mental health of an estimated fifty-three percent of adults³.

Medibio intends to address this increased need and demand for mobile mental health services through the development and launch of its Consumer App, which the Company plans to make available on Android and IOS platforms, with an expected commercial launch in advance of Mental Health Awareness Week in the United States in October 2021.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

¹ U.S. Patent "Method and System for Monitoring Stress Conditions" granted 5th May 2020.

² <https://www.grandviewresearch.com/industryanalysis/mhealth-app-market>

³ <https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/>

ASX Announcement

Medibio Limited – 11 January 2021



About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

WE Communications

T: +61 (0) 404 369 388

WE-AUMedibio@we-worldwide.com